Final FDA Guidance on Comparability Protocols
Recommendation
23/24 October 2024
Requirements, Challenges & Solutions
The U.S. Food and Drug Administration (FDA) released the final guidance on Comparability Protocols (CPs) for postapproval CMC changes. The revised guidance follows the draft version issued in April 2016.
Changes to the draft version
Among the changes are the following:
- Incorporation of the ICH Q12 principles for postapproval changes.
- Allowing API supplier changes to be made via CPs.
- Expanding the scope of the guidance to address CPs for drug master files (DMFs) and drug-device combination products (where CDER or CBER is the lead center).
The CP may be submitted as part of the original application or in a prior approval supplement (PAS).
Additionally, the guidance provides a "Questions and Answers" section on CPs in the Appendix, which covers changes to
- Formulations
- Facilities
- Processes
- Equipment
- Specifications (including Analytical Procedures)
- Packaging
- Process Analytical Technology (PAT)
- Drug-Device or Biologic-Device Combination Products
- DMFs
More information is available in FDA´s Guidance for Industry Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA.
Related GMP News
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years
30.04.2024Lean GMP: is "right-sizing" GMP and Compliance possible?
24.04.2024Unexpected Deviations: the Role of the QP
10.04.2024FDA's current Thinking on KPIs and Quality Metrics
21.02.2024What is the African Medicines Agency?